5-Fluorouracil, interferon-α-2b and cisplatin (PAP) for advanced urothelial cancer. A phase II study

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 373-378

  Kosmidis, P A ^a,d   Bacoyiannis, C ^a   Fountzilas, G ^b   Aravantinos, G ^c   Tsavaris, N ^a   Milathianakis, C ^a   Skarlos, D ^c  

^a METAXA CANCER HOSPITAL   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d Hellenic Co operative Oncology Group   (Greece)

Author keywords

Chemotherapy; Urothelial cancer

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PELVIS CARCINOMA; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; URETER CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; UROGENITAL NEOPLASMS; UROTHELIUM;

EID: 0030976155     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008287814252     Document Type: Article

References (23)

1. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-58.
2. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-5.
3. Loehrer PJ, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066-73.
4. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate and vinblastine (CMV): An effetive chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study. J Clin Oncol 1985; 3: 1463-70.
5. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987; 60: 574-85.
6. Niijima T. Phase II study of interferon-α-2A for tumors of urogenital tract. Jpn Clin Med Pharmacol 1985; 1: 395-406.
7. Wadler S, Schwartz EL, Wersto R et al. Interferon (IFN) modulates the activity 5-fluorouracil against two human colon cancer cell lines. Proc Am Assn Cancer Res 1989; 30: 569 (Abstr 2264).
8. Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 1988; 48: 4868-73.
9. Wadler S, Schwartz EL, Goldman M et al. Fluorouracil and recombinant alfa-2-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769-75.
10. Bowman A, Fergusson RJ, Allan SG et al. Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): A phase II study. Ann Oncol 1990; 1: 351-3.
11. Kish JA, Weaver A, Jacobs J et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819-24.
12. Keane TE, Gingrich JR, Rosner G et al. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: Analysis of cisplatin and or 5-fluorouracil in an in vivo survival model. Cancer Res 1994; 54: 475-81.
13. Logothetis CJ, Hossan E, Sella A et al. Fluorouracil and recombinant human interferon alfa-2A in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 1991; 83: 285-8.
14. Logothetis C, Dieringer P, Ellerhorst J et al. A 61% response rate with 5-fluorouracil, interferon-23 and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma. Proc Am Assoc Cancer Res 1992; 33: 221 (Abstr 1323).
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. Scher HI, Norton L. Chemotherapy for urothelial tract malignancies: Breaking the deadlock (review). Semin Surg Oncol 1992; 8: 316-41.
17. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-7.
18. Logothetis CJ, Finn LD, Smith T et al. Escalated MVAC with or without recombinant human granulocyte macrophage colony stimulating factor for the initial treatment of advanced malignant urothelial tumors. Results of a randomized trial. J Clin Oncol 1995; 13: 2272-7.
19. Fossa SD, Harland SJ, Kaye SB et al. Initial combination chemotherapy with cisplatin. methotrexate and vinblastine in locally advanced transitional cell carcinoma-response rate and pitfalls: MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party). Br J Urol 1992; 70: 161-8.
20. Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12: 2264-70.
21. Tu SM, Hossan E, Amato R et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 1995; 154: 1719-22.
22. Seidman AD, Scher HI, Heinemann MH et al. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 1991; 68: 2561-5.
23. Einhorn LH, Roth BJ, Ansari R et al. Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994; 12: 2271-6.